Suppr超能文献

局部应用0.3%环丙沙星、诺氟沙星和氧氟沙星治疗细菌性角膜炎:一种比较评估眼用药物渗透性的新方法。

Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration.

作者信息

Diamond J P, White L, Leeming J P, Bing Hoh H, Easty D L

机构信息

University of Bristol, Department of Ophthalmology, Bristol Eye Hospital.

出版信息

Br J Ophthalmol. 1995 Jun;79(6):606-9. doi: 10.1136/bjo.79.6.606.

Abstract

AIMS

This study was designed to assess the relative corneal penetration of topical drops of three antibiotics and to relate those levels to minimum inhibitory concentrations for organisms associated with bacterial keratitis.

METHODS

Four drops of each of ciprofloxacin, norfloxacin, and ofloxacin (0.3% topical ophthalmic preparations) were given to 12 patients undergoing corneal transplantation. After the recipient tissue was removed, corneal drug penetration was measured using high performance liquid chromatography.

RESULTS

Intracorneal concentrations of ofloxacin (geometric mean 0.81 mg kg-1) were significantly higher than both ciprofloxacin (0.60 mg kg-1; p = 0.048) and norfloxacin (0.54 mg kg-1; p = 0.012). Ciprofloxacin and norfloxacin concentrations did not differ significantly (p = 0.33).

CONCLUSIONS

Review of the minimum inhibitory concentrations of the fluoroquinolones against ocular pathogens reveals that ciprofloxacin is more potent than ofloxacin against many bacteria; ofloxacin is in turn more potent than norfloxacin. These data favour the selection of ciprofloxacin and ofloxacin rather than norfloxacin for the empirical treatment of corneal infection. The greater potency of ciprofloxacin offsets the superior penetration of ofloxacin. There is a need for improved clinical trial data concerning the use of fluoroquinolone eyedrops in ulcerative keratitis; some encouraging data are available for ciprofloxacin but not (in humans) for norfloxacin or ofloxacin.

摘要

目的

本研究旨在评估三种抗生素局部滴眼液的相对角膜穿透性,并将这些水平与细菌性角膜炎相关病原体的最低抑菌浓度相关联。

方法

给12例接受角膜移植的患者分别滴入4滴环丙沙星、诺氟沙星和氧氟沙星(0.3%局部眼科制剂)。受体组织切除后,采用高效液相色谱法测量角膜药物穿透性。

结果

氧氟沙星的角膜内浓度(几何均值0.81mg·kg⁻¹)显著高于环丙沙星(0.60mg·kg⁻¹;p = 0.048)和诺氟沙星(0.54mg·kg⁻¹;p = 0.012)。环丙沙星和诺氟沙星的浓度差异不显著(p = 0.33)。

结论

回顾氟喹诺酮类药物对眼部病原体的最低抑菌浓度发现,环丙沙星对许多细菌的抗菌活性比氧氟沙星更强;氧氟沙星又比诺氟沙星更强。这些数据支持在角膜感染的经验性治疗中选择环丙沙星和氧氟沙星而非诺氟沙星。环丙沙星更强的抗菌活性抵消了氧氟沙星更好的穿透性。需要有关于氟喹诺酮类滴眼液在溃疡性角膜炎中应用的改进的临床试验数据;环丙沙星有一些令人鼓舞的数据,但诺氟沙星和氧氟沙星(在人类中)没有。

相似文献

2
Treatment of experimental bacterial keratitis with topical trovafloxacin.
Arch Ophthalmol. 2004 Jan;122(1):65-9. doi: 10.1001/archopht.122.1.65.
3
Penetration of ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor using different topical application modes.
Graefes Arch Clin Exp Ophthalmol. 1999 Feb;237(2):89-92. doi: 10.1007/s004170050200.
5
Penetration of topically applied ciprofloxacin, norfloxacin, and ofloxacin into the aqueous humor.
Ophthalmology. 1994 May;101(5):902-5. doi: 10.1016/s0161-6420(13)31248-2.
8
Fluoroquinolones in the treatment of bacterial keratitis.
Am J Ophthalmol. 1996 Jun;121(6):712-5. doi: 10.1016/s0002-9394(14)70641-5.
9
Penetration of topically applied ciprofloxacin and ofloxacin into the aqueous humor and vitreous.
J Cataract Refract Surg. 2003 Mar;29(3):487-91. doi: 10.1016/s0886-3350(02)01538-9.

引用本文的文献

1
Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases.
Int J Nanomedicine. 2025 Jul 21;20:9221-9249. doi: 10.2147/IJN.S532074. eCollection 2025.
2
Cefiderocol Is an Effective Topical Monotherapy for Experimental Extensively Drug-Resistant Keratitis.
Ophthalmol Sci. 2023 Dec 13;4(4):100452. doi: 10.1016/j.xops.2023.100452. eCollection 2024 Jul-Aug.
3
Next-generation nanomaterials: advancing ocular anti-inflammatory drug therapy.
J Nanobiotechnology. 2023 Aug 19;21(1):282. doi: 10.1186/s12951-023-01974-4.
5
Lens concentration of ofloxacin and lomefloxacin in an experimental endophthalmitis model.
Curr Ther Res Clin Exp. 2007 May;68(3):184-90. doi: 10.1016/j.curtheres.2007.06.003.
6
In vitro antibiotic susceptibility patterns of bacterial keratitis isolates in Oxford, UK: a 10-year review.
Eye (Lond). 2011 Apr;25(4):489-93. doi: 10.1038/eye.2010.231. Epub 2011 Jan 21.
7
Ciprofloxacin as ocular liposomal hydrogel.
AAPS PharmSciTech. 2010 Mar;11(1):241-6. doi: 10.1208/s12249-009-9373-4. Epub 2010 Feb 12.
8
Intraocular penetration of sequentially instilled topical moxifloxacin, gatifloxacin, and levofloxacin.
Clin Ophthalmol. 2009;3:553-7. doi: 10.2147/opth.s7757. Epub 2009 Oct 19.
10
Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye.
Graefes Arch Clin Exp Ophthalmol. 2006 Dec;244(12):1633-7. doi: 10.1007/s00417-006-0360-0.

本文引用的文献

1
Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis.
Am J Ophthalmol. 1993 Apr 15;115(4):471-7. doi: 10.1016/s0002-9394(14)74449-6.
2
Corneal stromal penetration of topical ciprofloxacin in humans.
Ophthalmology. 1993 Feb;100(2):197-200. doi: 10.1016/s0161-6420(13)31672-8.
3
Penetration of topically applied ciprofloxacin, norfloxacin, and ofloxacin into the aqueous humor.
Ophthalmology. 1994 May;101(5):902-5. doi: 10.1016/s0161-6420(13)31248-2.
4
The comparative in-vitro activity of ofloxacin.
J Antimicrob Chemother. 1988 Sep;22 Suppl C:9-19. doi: 10.1093/jac/22.supplement_c.9.
6
Ulcerative keratitis associated with contact lens wear.
Am J Ophthalmol. 1989 Jul 15;108(1):64-7. doi: 10.1016/s0002-9394(14)73262-3.
7
In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents.
J Antimicrob Chemother. 1989 Apr;23(4):527-35. doi: 10.1093/jac/23.4.527.
10
Microbiologic aspects of fluoroquinolones.
Am J Ophthalmol. 1991 Oct;112(4 Suppl):15S-24S.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验